What is it about?
This study provides a potential new treatment to protect immunosuppressed patients from human cytomegalovirus (HCMV). It shows that certain drugs expose and help to destroy dormant HCMV infections, which often reactivate to cause serious illness and death in these vulnerable groups.
Featured Image
Why is it important?
This proposed ‘shock and kill’ treatment strategy against HCMV offers the possibility of reducing HCMV-mediated disease and death in transplant patients post-operation across the world.
Perspectives
This novel therapeutic avenue should be 'game changer' for solid organ and haematopoietic stem-cell/bone marrow transplant surgeons and patients in its ability to save lives.
Ian Groves
University of Cambridge
Read the Original
This page is a summary of: Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention, Proceedings of the National Academy of Sciences, February 2021, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2023025118.
You can read the full text:
Resources
Contributors
The following have contributed to this page
